EXPANDING THE ROLE OF COMMUNITY PHARMACY: AN EVALUATION OF GENERIC DRUG DISCOUNT PROGRAMS, PHARMACY BASED IMMUNIZATION SERVICES AND CONVENIENT CARE CLINICS

Jeffrey C. Keimer and Shaker A. Mousa*

Albany College of Pharmacy and Health Sciences, One Discovery Drive, Rensselaer, NY, 12144, USA

*Corresponding author e-mail: shaker.mousa@acphs.edu

ABSTRACT
We evaluated the clinical and economic impact of generic drug discount programs (GDDPs), pharmacy based immunization services and convenient care clinics (CCCs) based upon existing literature, reviewing original research and case study reports using library databases, primarily MEDLINE and EBSCOHost. Keywords used included “generic discount list,” “four dollar generic,” “pharmacy immunization,” “flu shot,” “pharmacist immunizer,” “convenient care clinic,” “retail health clinic,” and “minute clinic.” We then added other terms such as “clinical impact,” “cost-effectiveness,” “outcomes,” and “perceptions.” While all 3 programs have the potential to clinically benefit patients and provide some level of cost-effectiveness, there are also concerns that need to be addressed. Some concerns include: a) GDDPs have the potential to cause fragmentation of care owing to patients going to other pharmacies in search of lower prices and prescription claims data not being captured by patients’ pharmacy benefit managers, b) GDDPs may be less cost effective in pharmacies with less purchasing power compared to larger chains, c) pharmacy based immunization services still face legal and social barriers that prevent pharmacists from being recognized as legitimate vaccine administrators, d) some insurance carriers still don’t pay for pharmacist-administered vaccinations, e) CCCs may not currently be located in areas that could best benefit from their services, f) CCCs may disrupt a patient’s continuity of care with their primary care physicians, and g) CCCs may hinder the efforts of pharmacists to expand their own professional roles by lessening the need for them to do so. Expanding the roles of community pharmacies has the potential to improve patient care by increasing patients’ access to healthcare services. While strong evidence exists to support pharmacist-delivered immunizations, less is known regarding GDDPs and CCCs. More studies are required to assess the clinical and economic questions raised regarding these types of programs.

Keywords: Community pharmacy, retail pharmacy, generic drug discount, pharmacists, immunizations, convenient care clinic, retail clinic and urgent care

INTRODUCTION
Over the past decade, the demand and total amount spent for healthcare services such as prescription drugs has steadily increased despite a recession 1. According to the National Association of Chain Drug Stores (NACDS), the number of prescription drugs dispensed in the US has increased at a rate of approximately 1.9% every year since 2003 with total prescriptions dispensed in 2009 reaching approximately 3.6 billion 2. Yet one study showed that pharmacy owners’ general perception is that reimbursement rates from both private and public insurance carriers are falling. Furthermore, drop in reimbursement rates has been cited as the reason for many pharmacies, particularly independents, closing 3. Taken together this means that despite increased demand for prescription drugs, there is less profitability in dispensing them.

On the patient’s side, these increased healthcare expenditures have led to larger monthly premiums,
increased plan deductibles, and more limitations on patients’ access to healthcare, i.e. plan-only physicians, stricter formularies, tier co-pay structures, and high deductible plans. This has forced many patients to stringently assess how much they spend on healthcare for themselves and their families. It can also lead to foregoing medical care as a cost saving strategy.

Faced with this situation, the US retail pharmacy industry has responded by further expanding the role of its community pharmacies outside of their traditional role as a dispensary. Some of the most prevalent programs are generic drug discount programs (GDDPs), pharmacy-based immunization services and convenient care clinics (CCCs). However, these types of programs have the potential to decrease patient utilization of other, better established areas of healthcare. Hence, the implementation of programs such as these in community pharmacy has caused quite a bit of controversy in both the pharmacy and greater healthcare communities. As such, it is important that we take a deeper look at these programs in terms of their clinical and economic impact as well as their potential problems.

**GENERIC DRUG DISCOUNT PROGRAMS**

The marketing of generic drugs has historically been the subject of much controversy in the healthcare industry. Most arguments against generic substitutions center on perceptions of generics being inferior to their brand counterparts despite showing bioequivalence. However, the cost savings benefits of generic medications in the marketplace are incontrovertible. In the period between 2000 and 2009, it was estimated that generic drugs saved the US healthcare system $824 billion. To reap the benefits of such savings, most insurance carriers have instituted tiered co-pay structures for their subscribers in order to "push" patients toward preferred drugs by using higher co-payments for non-preferred drugs. This tactic has been shown to reduce spending on prescription drugs, but may cause additional spending due to inadequate therapy. This observation is backed up by data that support a correlation between medication non-adherence and increased cost. Therefore, it is important that this issue be addressed in order for patients to have the best possible clinical outcomes. GDDPs have been an increasingly popular way for most pharmacy chains to attract new business from people who have no prescription drug coverage or who struggle to pay high or multiple copayments every month. The first large scale implementation of a GDDP came in 2006, when a major mass merchant introduced a list of generic medications that would be available without insurance for $15 for a 90 day supply. Later that year, another mass merchant came out with a program that offered 30 day supplies on select generics for $4 without insurance or additional fees. The popularity of the latter program has since caused most other major pharmacy chains and some independents to create programs of their own. Although all programs offered aren’t the same, they all offer a similar service: lower cost options that expand access to prescription drugs to patients otherwise unable to afford them. Table 1 lists the top 10 prescription drugs on the market and their availability in a GDDP.

But how can this type of program be seen as expanding the role of the community pharmacy? The answer is simple: GDDPs function much like a supplementary insurance plan. Although GDDPs are technically not insurance, it stands to reason that a patient could use a GDDP to supplement their existing coverage or possibly forgo prescription coverage entirely. According to one field study, GDDPs represented an option for seniors who fell into the “donut hole” in their Medicare coverage to continue getting their medications at a reasonable rate. GDDPs may also serve the interests of pharmacy benefit managers (PBMs) by decreasing the number of claims paid out for generic medications and therefore pass major savings to PBMs. However, whether or not these savings will translate to lower premiums for subscribers is still unclear.

Aside from the potential benefits to insurers, there are also numerous potential benefits for pharmacies with GDDPs, the first of which is increased prescription volume and revenue. A case study published in 2010 studied the effects of implementing a GDDP. The main question of the study was whether or not the implementation of a GDDP would increase pharmacy volume and revenue. The conclusion was that the GDDP increased patients’ access to medications while also increasing prescription volume and the pharmacy’s net revenue. The results of this study may be limited however by the fact that the 340B pharmacy is a government subsidized entity that has access to prescription medications at significantly reduced prices. This would mean that GDDPs have been shown to be effective business strategies for pharmacies that can obtain medications at lower costs. Specifically, this would apply to pharmacies with larger purchasing power. Additional studies are needed to tell whether or not a GDDP is profitable in small chain or independent pharmacies with less purchasing power.
There are however, some concerns attached to GDDPs. Mainly, these concerns have to do with the incentive GDDPs give to patients to shop different pharmacies for better prices. A 1996 Canadian study showed that patients receiving medications from more than one pharmacy were at higher risk for possibly inappropriate drug combinations. Since then it has become widely accepted that patients visiting multiple pharmacies that don’t share medication records put themselves at higher risk for medication related problems. In fact, one of the main reasons that the 340B pharmacy in the aforementioned study implemented a GDDP was that patients were visiting other pharmacies, compromising their continuity of care. And pharmacists aren’t the only ones concerned with GDDPs. An article published in The New England Journal of Medicine in 2010 identified GDDPs as potentially dangerous because prescription claim data aren’t submitted to the patient’s PBM. According to the article, pharmacy claims data are used for pharmaceutical quality improvement in large populations. Pharmacy chains that have GDDPs may be unintentionally undermining this process because claims aren’t submitted to the PBMs. However, while the cause for concern with these programs for these reasons is legitimate as of right now, this is all speculation. More studies are needed to assess the impact GDDPs have on medication misuse.

PHARMACY BASED IMMUNIZATION SERVICES

According to the CDC, vaccines are considered one of the top 10 great public health achievements of the 20th century. Traditionally, these immunizations have been administered solely by physicians and nurses in settings such as their own offices, clinics, hospitals or other similar conventional immunization providers. However, since 1984, there has been a dramatic increase in the number of patients being immunized at “non-traditional” sites such as community pharmacies, supermarkets and nursing homes. A survey taken in 2005 estimated that 30% of all influenza vaccinations were administered at these “non-traditional” sites. Also, it’s been shown that younger, working aged patients tend to prefer these types of sites over conventional ones. This is most likely due to the convenience of being able to walk in to one of these settings without an appointment. Pharmacists have long been advocates of immunizations and since 1994 have also had the privilege of being facilitators. And, as of September 12, 2009, all 50 states with the exception of the District of Columbia now permit pharmacists to immunize. Expanding pharmacy practice to include administration of vaccines has largely been accepted as a benefit to public health. In a position paper published in 2002, the American College of Physicians stated that pharmacist-delivered immunizations stand to decrease antibiotic resistance and increase adult immunization owing to the greater accessibility patients have to pharmacists compared to physicians. This will undoubtedly become very important given the call from the CDC to expand influenza vaccinations to all patients 6 months of age or older. While some states allow pharmacists to administer any vaccine, most only allow pharmacists to administer influenza and pneumococcal vaccines. Given that, this review will focus primarily on influenza and pneumococcal immunizations.

Annual influenza vaccination has been shown to be clinically beneficial to patients regardless of age, and cost beneficial to patients over the age of 65. But what data exist to support pharmacist-delivered influenza vaccination? Immunizations at “non-traditional” sites administered by pharmacists were shown to be cost saving or relatively cost effective in healthy adults aged 18-64 and in adults 65 and older. These findings can be attributed to the fact that patients didn’t need to go out of their way to schedule an appointment, which can be burdensome for patients unable to do so during normal working hours. Also, net cost per person associated with procuring a vaccination from the pharmacist was almost 10-fold lower on average than vaccinations administered at traditional settings and almost half that of vaccinations administered at other public places by a non-pharmacist. However, the conclusions made in this study were based on data with a relatively low sample size of 12 sites. More studies regarding cost effectiveness of pharmacy based immunization with larger sample sizes are needed in order to make a more solid conclusion regarding the cost-benefit of pharmacist-delivered immunizations.

When it comes to offering vaccinations, there have been two approaches taken by pharmacists: single day offerings (vaccination clinics) and continuous offerings (walk in at any time). When studied, pharmacies that offered vaccinations at any time tended to administer many more vaccinations than pharmacies that only offered vaccinations on specific days. However, an issue facing many pharmacists is how to incorporate immunizations into the pharmacy’s workflow. The problem lies in how to provide daily immunization offerings while not causing undue burden upon processing times for other prescriptions and creating a need to hire extra...
pharmacists. While other methods may exist, a few tactics used to combat this problem are: treating the immunization just like another prescription, offering immunizations only at certain times during the day and asking that patients call ahead to schedule a time. However, while the last two methods certainly ease the burden on workflow, they also decrease patient access. More studies are needed to determine the optimal method of incorporating immunization services into daily pharmacy workflow while at the same time maintaining a high level of access for patients.

In addition to potential workflow issues, there are other problems with the expansion of pharmacist-delivered immunization services. First, there are the remaining legal barriers for pharmacists to immunize. Beyond the aforementioned limitation on types of vaccines administered by pharmacists, some states also have an age requirement for pharmacist-administered immunizations. For example, New York currently limits this service to patients 18 years and older. While earlier studies have hinted that the general public has had some uneasiness regarding pharmacists delivering immunizations to children, it is important to note that the choice of provider is still left up to the patient or their legal guardian. Provided with adequate training, there shouldn’t be any reason to deny pharmacists the authority to administer vaccines to children and adolescents. The other issue is the out of pocket cost for the patient. While Medicare and Medicaid cover flu shots, other insurance carriers may not. Also, some plans require that patients receive the vaccination at their physician’s office. This leaves many patients still unable or unwilling to pay for vaccination and they are not getting vaccinated despite expanded access.

CONVENIENT CARE CLINICS

A common problem that many Americans face is what to do when dealing with a minor ailment that still requires professional medical attention. Traditionally, options included a visit to the patient’s primary care physician’s office, an urgent care clinic or the emergency department at a local hospital. However, since 2000, a new option has emerged: the convenient care (CCC). Also known as retail health clinics or store-based health clinics, a CCC is an urgent care facility that’s located in a retail facility such as a drug store or supermarket. Such facilities cater to patients seeking care for a limited variety of common ailments that require treatment or immunizations (Table 2). CCCs are staffed by midlevel practitioners, mostly nurse practitioners who usually have collaboration with or oversight by an offsite physician. However, because licensed physicians aren’t present at CCCs, the scope of services offered is often limited. Patients who complain of more serious acute ailments or chronic medical problems are referred to a primary care provider.

But what evidence is there to support the continued existence of CCCs? Mainly, supporters of CCCs cite increased accessibility and decreased cost compared to other healthcare sites. According to a fact sheet from the Convenient Care Association (CCA), most CCCs are open 7 days a week with extended weekend hours and don’t require an appointment. This increased accessibility has been shown to be advantageous for CCCs. The appointment wait time was shown to be the major driver for patients when deciding from whom (physician or non-physician) to receive care for minor illnesses. These findings represent a clear advantage for CCCs over other care sites in terms of patient preference. However, a 2007 survey indicated that approximately 98% of Americans have never used a CCC. This can be attributed to the fact that CCCs are not widespread. The CCA reports that approximately 1,200 CCCs are in operation in 32 states across the country. By comparison, the American Academy of Urgent Care Medicine reports that there are approximately 8,000 urgent care facilities and hospital emergency department serving as sites of urgent care. In addition, CCCs are primarily located around economically advantaged neighborhoods in major metropolitan areas. Given this geographical distribution, one study concluded that CCCs may currently lack the ability to extend healthcare access to the underserved and uninsured. Simply put, CCCs may currently be situated in markets that may not be very demanding of their services. However, it’s difficult for CCCs to penetrate underserved markets because by definition, these areas may lack the existing infrastructure necessary to accommodate a CCC (i.e. pharmacies and supermarket).

The other suggested advantage of CCCs over other urgent care sites is lower cost to the patient. And indeed, CCCs do offer patients urgent care for the limited set of ailments they treat at a lower comparative cost. One study showed that the costs of treating 3 common illnesses (otitis media, pharyngitis, and urinary tract infections) were significantly lower at a CCC compared to other sites while offering the same or better quality of care. These findings were consistent with an earlier study that showed that costs per episode of illnesses treated at CCCs were lower than when patients were treated at other sites. However, the authors expressed an
important concern: Will lower costs for urgent care services increase demand and by consequence increase overall healthcare spending? More studies are needed to answer this question because care from CCCs currently doesn’t comprise a significant share of total US healthcare spending.

Besides potential economic issues with CCCs, other concerns have also been raised. Some of the primary clinical concerns physicians may have with CCCs have been outlined. Most notable was the potential for patients to lack continuity of care. This concern was based on the theory that patients who frequent CCCs are unlikely to seek out a primary care physician. Also, the author expressed concerns that potentially serious conditions could be overlooked by midlevel practitioners at CCCs. However, no studies have specifically addressed these concerns and any potential for patient harm for these reasons is still theoretical at this time. Another potential issue with CCCs relates to the pharmacists who often work alongside these clinics. Concern about sharing pharmacy space with other healthcare providers has been expressed, stating that CCCs may serve as either a barrier or an avenue for expanding the clinical roles of pharmacists. If other healthcare providers set up shop in the pharmacy, pharmacists may have problems securing additional space for other direct patient care services such as medication therapy management. Yet, despite the potential for a “turf war” in the pharmacy, CCCs may serve as a gateway for pharmacists into expanded clinical roles. In states that allow pharmacists prescribing authority, it’s feasible that these CCCs could be run by pharmacist clinicians. Such a role could position pharmacists to take on other collaborative practice agreements with physicians and further legitimize pharmacists as members of the overall healthcare team. Either way, it’s still uncertain what impact, if any, CCCs will have on expanding the roles of community pharmacists.

CONCLUSION

Expanding the role of the community pharmacy has the potential to benefit patients by increasing their access to healthcare. This is achieved by lowering costs sustained by patients as well as providing some services such as immunizations and acute care, at extended hours compared to other healthcare facilities. However, despite increasing access to healthcare a number of concerns still exist regarding the clinical and economic outcomes of these types of services. While there is strong evidence to support pharmacy based immunization services, it is still relatively unclear whether GDDPs and CCCs are both clinically and economically beneficial. More studies regarding GDDPs and CCCs will be necessary as both simply lack the histories from which to derive extensive data. However, while there may be advantages and disadvantages to each of these programs, patients only stand to benefit if they know about them. Educating patients about the opportunities of such programs is essential if these programs are to be successful. Though much is uncertain regarding the future of US healthcare, expanding the roles played by community pharmacies seeks to improve patient access and lower costs.

Table 1: GDDPs and the Top 10 Prescription Medications

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Generic Availability?</th>
<th>Present in a GDDP?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clopidogrel 75mg (Plavix)</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Hydrochlorothiazide 25mg (Hydrodiuril)</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Omeprazole 20mg (Prilosec)</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Furosemide 40mg (Lasix)</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Amlodipine 5mg (Norvasc)</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Esomeprazole 40mg (Nexium)</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Alendronate 70mg (Fosamax)</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Atorvastatin 10mg (Lipitor)</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Simvastatin 20mg (Zocor)</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Furosemide 20mg (Lasix)</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Source: Data on frequency of prescriptions are from the NYS EPIC Annual Report to the Governor & Legislature2008-09; information on GDDP availability is from Wal-Mart and Rite Aid.
Table 2: Example of Typical Services and Prices Offered by CCCs

<table>
<thead>
<tr>
<th>Type of Service</th>
<th>Chief Complaints/Services</th>
<th>Typical Pricing (US Dollars)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minor Illness Exam</td>
<td>Symptoms indicative of common illnesses such as respiratory infections, urinary tract infections, allergies.</td>
<td>79-89</td>
</tr>
<tr>
<td>Minor Injury Exams</td>
<td>Non-life threatening injuries that may require medical attention to alleviate pain and irritation and promote quicker healing. Also removal of foreign bodies such as splinters and sutures.</td>
<td>79-89</td>
</tr>
<tr>
<td>Skin Condition Exams</td>
<td>Non-life threatening conditions including acne, minor infections, minor rashes, wart removal, oral sores and lice.</td>
<td>79-89</td>
</tr>
<tr>
<td>Wellness and Physical Health Condition Exams</td>
<td>Screening services for patients at risk for more serious chronic health conditions such as hypertension, hyperlipidemia, diabetes and asthma as well as required physicals.</td>
<td>27-69</td>
</tr>
<tr>
<td>Monitoring Vaccinations</td>
<td>Monitor patients with an established diagnosis for a chronic condition such as hypertension, hyperlipidemia, diabetes or asthma.</td>
<td>59-89</td>
</tr>
<tr>
<td>Labs and Tests</td>
<td>Limited array of lab tests designed to help diagnose patients with common infections and aid in screening for pregnancy, asthma, hyperlipidemia or diabetes.</td>
<td>15-33</td>
</tr>
</tbody>
</table>

Source: CVS Pharmacy Minute Clinic: Services and Costs

REFERENCES

31. AAUCM. Know Where to Go. 2011 [cited 2011 03/19/2011]; Available from: http://aaucm.org/Patients/SelectUrgentCareCenter/default.aspx